Sustained virologic response after therapy with the HCV protease inhibitor narlaprevir in combination with peginterferon and ribavirin is durable through long-term follow-up-Reference-Cited by-同舟云学术

Sustained virologic response after therapy with the HCV protease inhibitor narlaprevir in combination with peginterferon and ribavirin is durable through long-term follow-up

Published:2013-01-07 Issue:4 Volume:20 Page:e78-e81
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:J Viral Hepat

Author:

Hotho D. M.¹,de Bruijne J.²,Spaan M.¹,Treitel M. A.³,Boonstra A.¹,de Knegt R. J.¹,Janssen H. L. A.¹,Reesink H. W.²

Affiliation:

1. Departments of Gastroenterology and Hepatology; Erasmus MC University Medical Center; Rotterdam the Netherlands

2. Departments of Gastroenterology and Hepatology; Academic Medical Center; Amsterdam the Netherlands

3. Department of Infectious Diseases and Hepatology; Merck Research Laboratories; Kenilworth NJ USA

Funder

Foundation for Liver Research

Publisher

Wiley

Subject

Virology,Infectious Diseases,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jvh.12012/fullpdf

Reference14 articles.

1. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases;Ghany;Hepatology,2011

2. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C;Maylin;Gastroenterology,2008

3. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection;Hezode;N Engl J Med,2009

4. Analysis of HCV resistance mutations during combination therapy with protease inhibitor boceprevir and PEG-IFN alpha-2b using TaqMan mismatch amplification mutation assay;Curry;J Virol Methods,2008

5. Inflammatory markers neopterin and alanine aminotransferase in HCV patients treated with HCV NS3.4A protease inhibitor telaprevir (VX-950) and/or peginterferon alfa-2a;Gelderblom;Scand J Gastroenterol,2008

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV2 main protease;PLOS ONE;2021-02-01

2. A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV-2 main protease;2020-07-10

3. Interferon down-regulation of miR-1225-3p as an antiviral mechanism through modulating Grb2-associated binding protein 3 expression;Journal of Biological Chemistry;2018-04

4. Direct-acting antivirals for chronic hepatitis C;Cochrane Database of Systematic Reviews;2017-09-18

5. Direct-acting antivirals for chronic hepatitis C;Cochrane Database of Systematic Reviews;2017-06-06